1
|
Friedman SL: Molecular regulation of
hepatic fibrosis, an integrated cellular response to tissue injury.
J Biol Chem. 275:2247–2250. 2000. View Article : Google Scholar : PubMed/NCBI
|
2
|
Pinzani M, Romanelli RG and Magli S:
Progression of fibrosis in chronic liver diseases: Time to tally
the score. J Hepatol. 34:764–767. 2001. View Article : Google Scholar : PubMed/NCBI
|
3
|
Malhi H and Gores GJ: Cellular and
molecular mechanisms of liver injury. Gastroenterology.
134:1641–1654. 2008. View Article : Google Scholar : PubMed/NCBI
|
4
|
Chen RJ, Wu HH and Wang YJ: Strategies to
prevent and reverse liver fibrosis in humans and laboratory
animals. Arch Toxicol. 89:1727–1750. 2015. View Article : Google Scholar : PubMed/NCBI
|
5
|
Yoon YJ, Friedman SL and Lee YA:
Antifibrotic therapies: Where are we now? Semin Liver Dis.
36:87–98. 2016. View Article : Google Scholar : PubMed/NCBI
|
6
|
Schuppan D: Liver fibrosis: Common
mechanisms and antifibrotic therapies. Clin Res Hepatol
Gastroenterol. 39(Suppl 1): S51–S59. 2015. View Article : Google Scholar : PubMed/NCBI
|
7
|
Toniutto P, Zanetto A, Ferrarese A and
Burra P: Current challenges and future directions for liver
transplantation. Liver Int. 37:317–327. 2017. View Article : Google Scholar
|
8
|
Jadlowiec CC and Taner T: Liver
transplantation: Current status and challenges. World J
Gastroenterol. 22:4438–4445. 2016. View Article : Google Scholar : PubMed/NCBI
|
9
|
Chang YJ, Liu JW, Lin PC, Sun LY, Peng CW,
Luo GH, Chen TM, Lee RP, Lin SZ, Harn HJ, et al: Mesenchymal stem
cells facilitate recovery from chemically induced liver damage and
decrease liver fibrosis. Life Sci. 85:517–525. 2009. View Article : Google Scholar : PubMed/NCBI
|
10
|
Sakaida I, Terai S, Yamamoto N, Aoyama K,
Ishikawa T, Nishina H and Okita K: Transplantation of bone marrow
cells reduces CCl4-induced liver fibrosis in mice.
Hepatology. 40:1304–1311. 2004. View Article : Google Scholar : PubMed/NCBI
|
11
|
Wu LM, Li LD, Liu H, Ning KY and Li YK:
Effects of Guiyuanfang and autologous transplantation of bone
marrow stem cells on rats with liver fibrosis. World J
Gastroenterol. 11:1155–1160. 2005. View Article : Google Scholar : PubMed/NCBI
|
12
|
Li TZ, Kim JH, Cho HH, Lee HS, Kim KS, Lee
SW and Suh H: Therapeutic potential of bone-marrow-derived
mesenchymal stem cells differentiated with growth-factor-free
coculture method in liver-injured rats. Tissue Eng Part A.
16:2649–2659. 2010. View Article : Google Scholar : PubMed/NCBI
|
13
|
Wang M, Zhang X, Xiong XI, Yang Z, Li P,
Wang J, Sun YU, Yang Z and Hoffman RM: Bone marrow mesenchymal stem
cells reverse liver damage in a carbon tetrachloride-induced mouse
model of chronic liver injury. In Vivo. 30:187–193. 2016.PubMed/NCBI
|
14
|
Truong NH, Nguyen NH, Le TV, Vu NB, Huynh
N, Nguyen TV, Le HM, Phan NK and Pham PV: Comparison of the
treatment efficiency of bone marrow-derived mesenchymal stem cell
transplantation via tail and portal veins in
CCl4-induced mouse liver fibrosis. Stem Cells Int.
2016:57204132016. View Article : Google Scholar
|
15
|
Shu SN, Wei L, Wang JH, Zhan YT, Chen HS
and Wang Y: Hepatic differentiation capability of rat bone
marrow-derived mesenchymal stem cells and hematopoietic stem cells.
World J Gastroenterol. 10:2818–2822. 2004. View Article : Google Scholar : PubMed/NCBI
|
16
|
Si-Tayeb K, Noto FK, Nagaoka M, Li J,
Battle MA, Duris C, North PE, Dalton S and Duncan SA: Highly
efficient generation of human hepatocyte-like cells from induced
pluripotent stem cells. Hepatology. 51:297–305. 2010. View Article : Google Scholar :
|
17
|
di Bonzo LV, Ferrero I, Cravanzola C,
Mareschi K, Rustichell D, Novo E, Sanavio F, Cannito S, Zamara E,
Bertero M, et al: Human mesenchymal stem cells as a two-edged sword
in hepatic regenerative medicine: Engraftment and hepatocyte
differentiation versus profibrogenic potential. Gut. 57:223–231.
2008. View Article : Google Scholar
|
18
|
Aurich I, Mueller LP, Aurich H,
Luetzkendorf J, Tisljar K, Dollinger MM, Schormann W, Walldorf J,
Hengstler JG, Fleig WE, et al: Functional integration of
hepatocytes derived from human mesenchymal stem cells into mouse
livers. Gut. 56:405–415. 2007. View Article : Google Scholar
|
19
|
Feng Z, Li C, Jiao S, Hu B and Zhao L: In
vitro differentiation of rat bone marrow mesenchymal stem cells
into hepatocytes. Hepatogastroenterology. 58:2081–2086. 2011.
View Article : Google Scholar : PubMed/NCBI
|
20
|
Eom YW, Shim KY and Baik SK: Mesenchymal
stem cell therapy for liver fibrosis. Korean J Intern Med.
30:580–589. 2015. View Article : Google Scholar : PubMed/NCBI
|
21
|
Shackel N and Rockey D: In pursuit of the
'Holy Grail' - stem cells, hepatic injury, fibrogenesis and repair.
Hepatology. 41:16–18. 2005. View Article : Google Scholar : PubMed/NCBI
|
22
|
Onda T, Honmou O, Harada K, Houkin K,
Hamada H and Kocsis JD: Therapeutic benefits by human mesenchymal
stem cells (hMSCs) and Ang-1 gene-modified hMSCs after cerebral
ischemia. J Cereb Blood Flow Metab. 28:329–340. 2008. View Article : Google Scholar :
|
23
|
Zeng B, Chen H, Zhu C, Ren X, Lin G and
Cao F: Effects of combined mesenchymal stem cells and heme
oxygenase-1 therapy on cardiac performance. Eur J Cardiothorac
Surg. 34:850–856. 2008. View Article : Google Scholar : PubMed/NCBI
|
24
|
Siller-López F, Sandoval A, Salgado S,
Salazar A, Bueno M, Garcia J, Vera J, Gálvez J, Hernández I, Ramos
M, et al: Treatment with human metalloproteinase-8 gene delivery
ameliorates experimental rat liver cirrhosis. Gastroenterology.
126:1122–1133. 2004. View Article : Google Scholar : PubMed/NCBI
|
25
|
Hu JJ, Sun C, Lan L, Chen YW and Li DG:
Therapeutic effect of transplanting beta(2)m(−)/Thy1(+) bone
marrow-derived hepatocyte stem cells transduced with
lentiviral-mediated HGF gene into CCl(4)-injured rats. J Gene Med.
12:244–254. 2010.PubMed/NCBI
|
26
|
Robert S, Gicquel T, Victoni T, Valença S,
Barreto E, Bailly-Maître B, Boichot E and Lagente V: Involvement of
matrix metalloproteinases (MMPs) and inflammasome pathway in
molecular mechanisms of fibrosis. Biosci Rep. 36:e003602016.
View Article : Google Scholar : PubMed/NCBI
|
27
|
Brinckerhoff CE and Matrisian LM: Matrix
metalloproteinases: A tail of a frog that became a prince. Nat Rev
Mol Cell Biol. 3:207–214. 2002. View
Article : Google Scholar : PubMed/NCBI
|
28
|
Takahara T, Furui K, Funaki J, Nakayama Y,
Itoh H, Miyabayashi C, Sato H, Seiki M, Ooshima A and Watanabe A:
Increased expression of matrix metalloproteinase-II in experimental
liver fibrosis in rats. Hepatology. 21:787–795. 1995. View Article : Google Scholar : PubMed/NCBI
|
29
|
Radbill BD, Gupta R, Ramirez MCM, DiFeo A,
Martignetti JA, Alvarez CE, Friedman SL, Narla G, Vrabie R, Bowles
R, et al: Loss of matrix metalloproteinase-2 amplifies murine
toxin-induced liver fibrosis by upregulating collagen I expression.
Dig Dis Sci. 56:406–416. 2011. View Article : Google Scholar
|
30
|
Issa R, Zhou X, Constandinou CM,
Fallowfield J, Millward-Sadler H, Gaca MDA, Sands E, Suliman I,
Trim N and Knorr A: Spontaneous recovery from micronodular
cirrhosis: Evidence for incomplete resolution associated with
matrix cross-linking. Gastroenterology. 126:1795–1808. 2004.
View Article : Google Scholar : PubMed/NCBI
|
31
|
Preaux AM, D'Ortho MP, Bralet MP, Laperche
Y and Mavier P: Apoptosis of human hepatic myofibroblasts promotes
activation of matrix metalloproteinase-2. Hepatology. 36:615–622.
2002. View Article : Google Scholar : PubMed/NCBI
|
32
|
Visse R and Nagase H: Matrix
metalloproteinases and tissue inhibitors of metalloproteinases:
Structure, function, and biochemistry. Circ Res. 92:827–839. 2003.
View Article : Google Scholar : PubMed/NCBI
|
33
|
Nagase H, Visse R and Murphy G: Structure
and function of matrix metalloproteinases and TIMPs. Cardiovasc
Res. 69:562–573. 2006. View Article : Google Scholar : PubMed/NCBI
|
34
|
Iimuro Y, Nishio T, Morimoto T, Nitta T,
Stefanovic B, Choi SK, Brenner DA and Yamaoka Y: Delivery of matrix
metal-loproteinase-1 attenuates established liver fibrosis in the
rat. Gastroenterology. 124:445–458. 2003. View Article : Google Scholar : PubMed/NCBI
|
35
|
Yang Q, Xie RJ, Geng XX, Luo XH, Han B and
Cheng ML: Effect of Danshao Huaxian capsule on expression of matrix
metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in
fibrotic liver of rats. World J Gastroenterol. 11:4953–4956. 2005.
View Article : Google Scholar : PubMed/NCBI
|
36
|
Du C, Jiang MD, Zeng WZ and Zheng SM:
Construction of recombinant adenovirus vector for human matrix
metalloproteinase-1 gene and detection of collagen type III
degradation in vitro. Chin J Tissue Eng Res. 7995–8000. 2014.In
Chinese.
|
37
|
Nadri S, Soleimani M, Hosseni RH, Massumi
M, Atashi A and Izadpanah R: An efficient method for isolation of
murine bone marrow mesenchymal stem cells. Int J Dev Biol.
51:723–729. 2007. View Article : Google Scholar : PubMed/NCBI
|
38
|
Soleimani M and Nadri S: A protocol for
isolation and culture of mesenchymal stem cells from mouse bone
marrow. Nat Protoc. 4:102–106. 2009. View Article : Google Scholar : PubMed/NCBI
|
39
|
Shiota G and Itaba N: Progress in stem
cell-based therapy for liver disease. Hepatol Res. May 18–2016.Epub
ahead of print. PubMed/NCBI
|
40
|
Haldar D, Henderson NC, Hirschfield G and
Newsome PN: Mesenchymal stromal cells and liver fibrosis: A
complicated relationship. FASEB J. 30:3905–3928. 2016. View Article : Google Scholar : PubMed/NCBI
|
41
|
Matsumoto T, Takami T and Sakaida I: Cell
transplantation as a non-invasive strategy for treating liver
fibrosis. Expert Rev Gastroenterol Hepatol. 10:639–648. 2016.
View Article : Google Scholar
|
42
|
Raafat N, Abdel AS, Abdo FK and El GN:
Mesenchymal stem cells: In vivo therapeutic application ameliorates
carbon tetrachloride induced liver fibrosis in rats. Int J Biochem
Cell Biol. 68:109–118. 2015. View Article : Google Scholar : PubMed/NCBI
|
43
|
Cho KA, Lim GW, Joo SY, Woo SY, Seoh JY,
Cho SJ, Han HS and Ryu KH: Transplantation of bone marrow cells
reduces CCl4-induced liver fibrosis in mice. Liver Int.
31:932–939. 2011. View Article : Google Scholar
|
44
|
Meier RP, Mahou R, Morel P, Meyer J,
Montanari E, Muller YD, Christofilopoulos P, Wandrey C,
Gonelle-Gispert C and Bühler LH: Microencapsulated human
mesenchymal stem cells decrease liver fibrosis in mice. J Hepatol.
62:634–641. 2015. View Article : Google Scholar
|
45
|
Kim MD, Kim SS, Cha HY, Jang SH, Chang DY,
Kim W, Suh-Kim H and Lee JH: Therapeutic effect of hepatocyte
growth factor-secreting mesenchymal stem cells in a rat model of
liver fibrosis. Exp Mol Med. 46:e1102014. View Article : Google Scholar : PubMed/NCBI
|
46
|
Irfan A and Ahmed I: Could stem cell
therapy be the cure in liver cirrhosis? J Clin Exp Hepatol.
5:142–146. 2015. View Article : Google Scholar : PubMed/NCBI
|
47
|
Mormone E, George J and Nieto N: Molecular
pathogenesis of hepatic fibrosis and current therapeutic
approaches. Chem Biol Interact. 193:225–231. 2011. View Article : Google Scholar : PubMed/NCBI
|
48
|
Garcia-Banuelos J, Siller-Lopez F, Miranda
A, Aguilar LK, Aguilar-Cordova E and Armendariz-Borunda J:
Cirrhotic rat livers with extensive fibrosis can be safely
transduced with clinical-grade adenoviral vectors. Evidence of
cirrhosis reversion. Gene Ther. 9:127–134. 2002. View Article : Google Scholar : PubMed/NCBI
|
49
|
Dong SW, Ying DJ, Duan XJ, Xie Z, Yu ZJ,
Zhu CH, Yang B and Sun JS: Bone regeneration using an acellular
extracellular matrix and bone marrow mesenchymal stem cells
expressing Cbfa1. Biosci Biotechnol Biochem. 73:2226–2233. 2009.
View Article : Google Scholar : PubMed/NCBI
|
50
|
Xu L, Huang S, Hou Y, Liu Y, Ni M, Meng F,
Wang K, Rui Y, Jiang X and Li G: Sox11-modified mesenchymal stem
cells (MSCs) accelerate bone fracture healing: Sox11 regulates
differentiation and migration of MSCs. FASEB J. 29:1143–1152. 2015.
View Article : Google Scholar
|
51
|
Yuan L, Sakamoto N, Song G and Sato M:
Low-level shear stress induces human mesenchymal stem cell
migration through the SDF-1/CXCR4 axis via MAPK signaling pathways.
Stem Cells Dev. 22:2384–2393. 2013. View Article : Google Scholar : PubMed/NCBI
|
52
|
Schichor C, Birnbaum T, Etminan N, Schnell
O, Grau S, Miebach S, Aboody K, Padovan C, Straube A, Tonn JC, et
al: Vascular endothelial growth factor A contributes to
glioma-induced migration of human marrow stromal cells (hMSC). Exp
Neurol. 199:301–310. 2006. View Article : Google Scholar : PubMed/NCBI
|
53
|
Schmidt A, Ladage D, Schinkothe T,
Klausmann U, Ulrichs C, Klinz FJ, Brixius K, Arnhold S, Desai B,
Mehlhorn U, et al: Basic fibroblast growth factor controls
migration in human mesenchymal stem cells. Stem Cells.
24:1750–1758. 2006. View Article : Google Scholar : PubMed/NCBI
|
54
|
Chung KM, Hsu SC, Chu YR, Lin MY, Jiaang
WT, Chen RH and Chen X: Fibroblast activation protein (FAP) is
essential for the migration of bone marrow mesenchymal stem cells
through RhoA activation. PLoS one. 9:e887722014. View Article : Google Scholar : PubMed/NCBI
|
55
|
Gebler A, Zabel O and Seliger B: The
immunomodulatory capacity of mesenchymal stem cells. Trends Mol
Med. 18:128–134. 2012. View Article : Google Scholar
|
56
|
Holmes C and Stanford WL: Concise review:
stem cell antigen-1: expression, function, and enigma. Stem Cells.
25:1339–1347. 2007. View Article : Google Scholar : PubMed/NCBI
|